<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03103152</url>
  </required_header>
  <id_info>
    <org_study_id>isrctn91422391</org_study_id>
    <nct_id>NCT03103152</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effectiveness of Aspirin and/or Vitamin D3 to Prevent Prostate Cancer Progression</brief_title>
  <acronym>PROVENT</acronym>
  <official_title>PROVENT: A Randomised, Double Blind, Placebo Controlled Feasibility Study to Examine the Clinical Effectiveness of Aspirin and/or Vitamin D3 to Prevent Disease Progression in Men on Active Surveillance for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen Mary University of London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barts and the London School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Research UK</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen Mary University of London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the acceptability and feasibility of recruitment to a randomised
      chemoprevention study of standard (300mg) or low dose (100mg) aspirin vs. placebo and/or
      Vitamin D3 vs. placebo in patients enrolled on an Active Surveillance programme for prostate
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PROVENT study is a randomised, double blind, placebo controlled feasibility study to
      examine the clinical effectiveness of aspirin and/or Vitamin D3 to prevent disease
      progression in men on Active Surveillance for prostate cancer

      The main outcome measure of the trial is the rate of patient recruitment to a randomised
      chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer

      Secondary outcomes include the response to treatment as determined by serial multi-parametric
      magnetic resonance imaging (MRI) of the prostate, biochemical disease progression and
      histological disease progression after 12 months of therapy and finally toxicity and/or
      allergy to both aspirin and Vitamin D3.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">October 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patient recruitment to a randomised chemoprevention study in men enrolled on an Active Surveillance programme for prostate cancer. Number accrued per month.</measure>
    <time_frame>12 months</time_frame>
    <description>The proportion of eligible patients that join the trial over the 12-month trial recruitment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to treatment as determined by serial multi-parametric magnetic resonance imaging (MRI) of the prostate. New lesion present or existing lesion + or - in size.</measure>
    <time_frame>3 years</time_frame>
    <description>Lesion on multi-parametric imaging where no MRI lesion at screening. An MRI scan shows a screening + or - in volume by &gt; 33%, or an upgrading of MRI stage of disease to ≥3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical disease progression.</measure>
    <time_frame>12 months</time_frame>
    <description>50% increase in serum Prostate Specific Antigen at 12 months from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histological disease progression. Increase in Gleason score or MCCL</measure>
    <time_frame>3 years</time_frame>
    <description>Histological disease progression will be defined as an increase in Gleason scores from: Gleason 3+3 to Gleason score 7 or higher Gleason 3+4 (score 7) to 4+3 (score 7) or Gleason 4+3 to a higher score
Or a 50% increase in maximum cancer core length (MCCL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity and/or allergy to both aspirin and Vitamin D3; Symptoms of Aspirin or Vit D toxicity.</measure>
    <time_frame>3 years</time_frame>
    <description>Aspirin toxicity: Haemorrhagic stroke, anaphylaxis following administration, gastrointestinal bleeding requiring intervention (both medical and surgical)
Vitamin D3 toxicity: Hypercalcaemia, Anaphylaxis</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>High dose Aspirin &amp; Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin high dose (300mgs) daily &amp; Vitamin D 4,000 IU (0.1mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>high dose aspirin (300mgs) daily and Vitamin D placebo (Miglyol®812 Oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Aspirin , Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose aspirin (100mgs) daily &amp; Vitamin D 4,000 IU (0.1mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose Aspirin, Vitamin D placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Low dose aspirin (100mgs) daily and Vitamin D placebo (Miglyol®812 Oil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo and Vitamin D active ingredient - Vigantol® Oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspirin placebo, Vitamin D placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aspirin placebo and Vitamin D placebo - Miglyol®812 Oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Aspirin &amp; Vitamin D</intervention_name>
    <description>Aspirin 1 x 300mg tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>High dose Aspirin &amp; Vitamin D</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Aspirin, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 300mg tablet daily &amp; Vitamin D placebo (8 drops).</description>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Aspirin , Vitamin D</intervention_name>
    <description>Aspirin 1 x 100mg tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <arm_group_label>Low dose Aspirin , Vitamin D</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Aspirin, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 100mg tablet daily &amp; Vitamin D placebo 8 drops daily.</description>
    <arm_group_label>Low dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin - acetylsalicylic acid</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin Placebo, Vitamin D</intervention_name>
    <description>Aspirin 1 x 300mg placebo tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin Placebo, Vitamin D</arm_group_label>
    <other_name>Vitamin D - Vigantol® Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin placebo, Vitamin D placebo</intervention_name>
    <description>Aspirin 1 x 100mg placebo tablet daily &amp; Vitamin D 4,000IU daily. (8 drops).</description>
    <arm_group_label>Aspirin placebo, Vitamin D placebo</arm_group_label>
    <arm_group_label>High dose Aspirin, Vitamin D placebo</arm_group_label>
    <other_name>Aspirin Placebo, Vitamin D</other_name>
    <other_name>Vitamin D placebo - Miglyol®812 Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Male subjects aged 16 years or over with an estimated life expectancy of more than
             three years

          2. Willing and able to provide written informed consent

          3. Corrected serum calcium ≤ 2.65mmol/l

          4. No previous treatment for prostate cancer (including surgery, hormone therapy,
             radiotherapy, cryotherapy)

          5. Must have undergone a multi-parametric MRI of the prostate, deemed assessable by the
             local radiologist, and any lesions seen must have undergone targeted biopsy,
             (transrectal or transperineal) within 12 months of study registration.

          6. Histologically confirmed prostate cancer* following prostate biopsy (including at
             least 10 cores of prostate tissue) in men opting for Active Surveillance as their
             primary cancer therapy.

               -  PROVENT Prostate Cancer Criteria. All must be met for Inclusion:

                    -  Gleason score 6 or 7 (Gleason 3+3 or 3+4)

                    -  Clinical and radiological stage &lt;T3

                    -  Serum Prostate Specific Antigen (PSA) ≤15.0 ng/ml

                    -  Less than 10mm of cancer in a single core

        Exclusion Criteria:

          1. Previously treated prostate cancer (including radiotherapy, hormone therapy,
             brachytherapy or surgery)

          2. Currently enrolled, or has been a participant within the last 30 days, in any other
             investigational drug or device study.

          3. Current daily use of aspirin or NSAIDs; or daily dietary supplements/medication
             containing more than 400 IU (10 micrograms per day) Vitamin D; or chronic use (defined
             as &gt; 6 months continuous daily use) of either aspirin or &gt;400IU Vitamin D within two
             years of study enrolment

          4. Current or previous use of 5-α reductase inhibitors such as finasteride or dutasteride

          5. Not willing to comply with the procedural requirements of this protocol including
             repeat prostate biopsies

          6. Known allergy/sensitivity to or intolerance of aspirin, other salicylates or NSAIDs
             e.g. ibuprofen/ naproxen

          7. Prior history of gastro-intestinal bleeding or ulceration, severe dyspepsia or
             inflammatory bowel disease

          8. Haemophilia or other bleeding diatheses

          9. Prior history of renal stone disease

         10. Chronic renal disease (≥stage 4)

         11. Known hypercalcaemia (corrected serum calcium &gt;2.65 mmol/l) or untreated
             hyperparathyroidism

         12. Any bowel condition that would make repeat transrectal biopsy hazardous or difficult
             to perform e.g. recto-urethral fistula, or prior bowel surgery such as
             abdomino-perineal resection.

         13. Any malignancy (other than non-melanoma skin cancer) that has not been in complete
             remission for five years

         14. Any serious co-existent medical condition that would make repeat prostate biopsy
             hazardous e.g. anti-coagulation requiring continuous administration

         15. Severe Asthma

         16. G6PD ( glucose-6-phosphate dehydrogenase) deficiency

         17. Pre-existing macular degeneration

         18. All contraindications to aspirin and Vitamin D3 (e.g. Sarcoidosis), including
             concomitant therapy with any medication that may interact with aspirin or Vitamin D3
             (see section 4.10)

         19. Tuberculosis

         20. Regular consumption of alcohol units greater than the recommended daily limit of 3-4
             units per day (men)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Greg Shaw, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jack Cuzick, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Queen Mary London</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Darent Valley Hospital</name>
      <address>
        <city>Dartford</city>
        <zip>DA2 8DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Wales</name>
      <address>
        <city>London</city>
        <zip>CF14 4XW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital UHCW NHS Trust</name>
      <address>
        <city>London</city>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Bartholomews Hospital London, Bart's and the London school of Medicine</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College Hospital London</name>
      <address>
        <city>London</city>
        <zip>NW1 2B</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Homerton Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>S016 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.provent.org.uk/</url>
    <description>PROVENT STUDY WEBSITE</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 21, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Active Surveillance</keyword>
  <keyword>Chemo-prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

